Mupirocin Infectopharm (Mupirocin)

Mupirocin is an antibacterial agent used for nasal decolonisation of Staphylococcus aureus.

• Nasal decolonisation of Staphylococcus aureus carriers: reduces bacterial load in the nares to lower infection risk.
• Prevention of nasal colonisation by MRSA: helps limit spread of methicillin‑resistant Staphylococcus aureus in high‑risk settings.
• Pre‑operative screening support: assists in preparing patients for surgery by eliminating nasal carriage of pathogenic staphylococci.
• Outbreak control in healthcare facilities: used as part of infection‑control protocols to curb staphylococcal transmission.

• Mupirocin inhibits bacterial isoleucyl‑tRNA synthetase, an enzyme required for incorporation of isoleucine into nascent proteins. By blocking this step, protein synthesis is halted, leading to bacterial growth arrest and cell death, particularly against Gram‑positive organisms such as Staphylococcus aureus, including methicillin‑resistant strains. The drug binds competitively to the active site, preventing aminoacyl‑tRNA formation and thereby disrupting the translational machinery of susceptible bacteria.

Mupirocin may cause local or systemic adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nasal irritation: mild burning, itching or stinging at the application site.
• Rhinorrhea: watery discharge from the nose.
• Headache: transient mild headache.
• Local erythema: redness of the nasal mucosa.
• Pruritus: itching around the nostrils.

Serious or Rare Side Effects

• Allergic contact dermatitis: severe skin reaction with swelling and blistering.
• Anaphylaxis: rare systemic hypersensitivity requiring immediate medical attention.
• Superinfection: overgrowth of non‑susceptible organisms such as fungi.
• Hepatotoxicity: very rare liver enzyme elevation.
• Stevens‑Johnson syndrome: extremely rare severe mucocutaneous reaction.

Before using Mupirocin, consider the following precautions to ensure safe and effective treatment.

• Contraindication: known hypersensitivity to mupirocin or any component of the formulation.
• Pregnancy: safety not established; use only if potential benefit justifies potential risk.
• Breastfeeding: limited data; weigh benefits against possible infant exposure.
• Pediatric use: safety and efficacy established for nasal decolonisation in children; follow prescriber guidance.
• Drug interactions: avoid concurrent use with other topical antibiotics on the same site to reduce resistance risk.
• Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight, and retain in original packaging.

Mupirocin can interact with other agents; awareness of significant interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Systemic antibiotics with overlapping spectrum: may promote resistance when used simultaneously on the same site.
• Antifungal nasal preparations: concurrent use can diminish antifungal effectiveness.

Moderate Interactions (Monitor Closely)

• Topical corticosteroids: may increase local absorption, potentially enhancing side effects.
• Nasal decongestants: could alter mucosal integrity, affecting drug distribution.
• Immunosuppressants: patients with weakened immunity may have higher risk of infection despite treatment.